Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSP NASDAQ:LIVN NASDAQ:TNDM NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$89.08+1.5%$121.60$73.92▼$225.00$2.64B1.22674,000 shs487,954 shsLIVNLivaNova$53.40-0.6%$45.70$32.48▼$57.35$2.92B0.92709,082 shs165,661 shsTNDMTandem Diabetes Care$11.06+2.2%$16.59$9.98▼$47.60$749.69M1.461.71 million shs903,871 shsWRBYWarby Parker$26.91-0.8%$23.10$12.69▼$29.73$2.84B2.092.25 million shs534,003 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems0.00%+10.72%-30.94%-41.50%-53.55%LIVNLivaNova0.00%+9.99%+27.97%+22.17%+16.68%TNDMTandem Diabetes Care0.00%-3.65%-26.74%-52.40%-75.79%WRBYWarby Parker0.00%+16.56%+13.88%+54.86%+87.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINSPInspire Medical Systems4.9197 of 5 stars4.34.00.04.83.81.71.9LIVNLivaNova2.3712 of 5 stars2.53.00.00.02.81.71.3TNDMTandem Diabetes Care4.5732 of 5 stars4.13.00.04.92.71.70.6WRBYWarby Parker2.1205 of 5 stars2.32.00.00.03.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.54Moderate Buy$165.6285.32% UpsideLIVNLivaNova 3.00Buy$59.2911.85% UpsideTNDMTandem Diabetes Care 2.20Hold$22.67105.04% UpsideWRBYWarby Parker 2.58Moderate Buy$24.06-10.75% DownsideCurrent Analyst Ratings BreakdownLatest TNDM, LIVN, WRBY, and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025INSPInspire Medical SystemsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$116.00 ➝ $97.008/11/2025TNDMTandem Diabetes CareLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $12.008/8/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$20.00 ➝ $23.008/8/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$53.00 ➝ $51.008/8/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$21.00 ➝ $22.008/7/2025WRBYWarby ParkerEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingPositive ➝ Positive8/7/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$59.00 ➝ $24.008/7/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$30.00 ➝ $14.008/7/2025TNDMTandem Diabetes CareUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$20.00 ➝ $17.008/7/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $13.00(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$802.80M3.29$1.74 per share51.37$23.01 per share3.88LIVNLivaNova$1.25B2.31$4.18 per share12.67$24.31 per share2.18TNDMTandem Diabetes Care$940.20M0.79N/AN/A$4.01 per share2.76WRBYWarby Parker$771.32M3.68$0.34 per share79.92$3.35 per share8.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$53.51M$1.7351.6127.752.746.17%10.38%8.93%11/3/2025 (Estimated)LIVNLivaNova$63.23M-$3.89N/A16.88N/A-16.13%14.57%6.91%10/29/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/5/2025 (Estimated)WRBYWarby Parker-$20.39M-$0.07N/A269.60N/A-1.12%-0.79%-0.41%11/6/2025 (Estimated)Latest TNDM, LIVN, WRBY, and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025LIVNLivaNova$0.84$1.05+$0.21$0.50$332.20 million$352.50 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million8/4/2025Q2 2025INSPInspire Medical Systems$0.22$0.45+$0.23-$0.12$214.50 million$217.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A6.144.84LIVNLivaNova0.311.291.09TNDMTandem Diabetes Care2.322.441.88WRBYWarby ParkerN/A2.552.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%LIVNLivaNova97.64%TNDMTandem Diabetes CareN/AWRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems2.30%LIVNLivaNova0.29%TNDMTandem Diabetes Care1.90%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,24629.57 million28.89 millionOptionableLIVNLivaNova2,90054.60 million54.44 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableWRBYWarby Parker3,780105.19 million86.00 millionOptionableTNDM, LIVN, WRBY, and INSP HeadlinesRecent News About These CompaniesWarby Parker Inc. (NYSE:WRBY) Stock Position Decreased by Deutsche Bank AGAugust 18 at 3:28 AM | marketbeat.comAigen Investment Management LP Takes Position in Warby Parker Inc. (NYSE:WRBY)August 16 at 4:28 AM | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Director Sells $141,360.00 in StockAugust 15 at 8:44 PM | marketbeat.comWarby Parker Inc. (NYSE:WRBY) CEO Neil Harris Blumenthal Sells 50,000 SharesAugust 15 at 8:43 PM | marketbeat.comStocks Showing Market Leadership: Warby Parker Earns 93 RS RatingAugust 14, 2025 | msn.comWarby Parker CFO Steve Miller ResignsAugust 14, 2025 | theglobeandmail.comTelsey Advisory Sticks to Its Buy Rating for Warby Parker (WRBY)August 14, 2025 | theglobeandmail.comThe 5 Most Interesting Analyst Questions From Warby Parker’s Q2 Earnings CallAugust 14, 2025 | finance.yahoo.comTeresa Briggs Sells 6,000 Shares of Warby Parker Inc. (NYSE:WRBY) StockAugust 14, 2025 | insidertrades.comConnor Clark & Lunn Investment Management Ltd. Has $5.09 Million Position in Warby Parker Inc. (NYSE:WRBY)August 14, 2025 | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Position Trimmed by AIA Group LtdAugust 13, 2025 | marketbeat.com236,623 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by King Luther Capital Management CorpAugust 13, 2025 | marketbeat.comWarby Parker’s Earnings Call: Growth and Strategic MovesAugust 13, 2025 | msn.comWRBY Q2 Deep Dive: Retail Expansion, AI Partnerships, and Margin Leverage Define the QuarterAugust 12, 2025 | msn.comWarby Parker Inc. (NYSE:WRBY) Shares Sold by Polen Capital Management LLCAugust 11, 2025 | marketbeat.comWarby Parker Gets Price Target Hikes On Strong Q2 Report, Google AI Glasses OptimismAugust 11, 2025 | msn.comHow Warby Parker Has Kept the Price of Glasses at $95 for 15 YearsAugust 10, 2025 | wsj.com21,662 Shares in Warby Parker Inc. (NYSE:WRBY) Acquired by XTX Topco LtdAugust 10, 2025 | marketbeat.comStifel Nicolaus Increases Warby Parker (NYSE:WRBY) Price Target to $22.00August 9, 2025 | marketbeat.comJefferies Financial Group Inc. Makes New $292,000 Investment in Warby Parker Inc. (NYSE:WRBY)August 9, 2025 | marketbeat.comZurcher Kantonalbank Zurich Cantonalbank Sells 64,236 Shares of Warby Parker Inc. (NYSE:WRBY)August 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNDM, LIVN, WRBY, and INSP Company DescriptionsInspire Medical Systems NYSE:INSP$89.08 +1.31 (+1.50%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.LivaNova NASDAQ:LIVN$53.40 -0.33 (-0.60%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.Tandem Diabetes Care NASDAQ:TNDM$11.06 +0.24 (+2.24%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Warby Parker NYSE:WRBY$26.91 -0.22 (-0.81%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Whirlpool A Screamin’ Buy in 2025? Signs Say Yes Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Why Arista's Blowout Q2 Is Good News for Chip-Giant Broadcom Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.